Fig. 4

Effects of vidarabine on AC5, NOX4, p-CaMKII, ox-CaMKII and phospho-PLN. a AC5 expression was similar in cardiac muscle of all four groups. NS; not significantly different. One-way ANOVA followed. by Tukey’s post hoc test) Full-size images of immunoblots are presented in Additional file 1: Fig. S3. b NOX4 expression was significantly increased in the cardiac muscle of PG-LPS group (n = 7, *P < 0.05), and this increase was significantly blocked in the PG-LPS + vidarabine group (n = 7, *P < 0.05). One-way ANOVA followed by Tukey’s post hoc test). Full-size images of immunoblots are presented in Additional file 1: Fig. S4. c Expression of phospho-CaMKII (Thr-286) was significantly increased in the PG-LPS group (n = 6, **P < 0.01), and this increase was significantly attenuated in the PG-LPS + vidarabine group (n = 7, **P < 0.01). One-way ANOVA followed by Tukey’s post hoc test). Full-size images of immunoblots are presented in Additional file 1: Fig. S5. d Expression of oxidized-CaMKII (ox-CaMKII) was significantly increased in the PG-LPS group (n = 4, *P < 0.01) and this increase was significantly attenuated in the PG-LPS + vidarabine group (n = 4, *P < 0.05). One-way ANOVA followed by the Tukey–Kramer post hoc test. Full-size images of immunoblots are presented in Additional file 1: Fig. S6. e Expression of phospho-PLN (Thr-17) was significantly increased in the PG-LPS group (n = 4, *P < 0.05), and this increase was significantly attenuated in the PG-LPS + vidarabine group (n = 5, *P < 0.01). One-way ANOVA followed by Tukey’s post hoc test). Full-size images of immunoblots are presented in Additional file 1: Fig. S7. Data are presented as mean ± SD and scattered dots show individual data